Clinical Trial Update: Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating first-line therapy with paclitaxel/carboplatin in combination with bevacizumab and erlotinib for carcinoma of unknown primary, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary

Drugs mentioned

• Avastin (bevacizumab)
• Paraplatin (Carboplatin)
• Tarceva (erlotinib)
• Taxol (paclitaxel)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Neoplasm, Unknown Primary | Phase 2 | Status: COMPLETED | Results posted: 2013-10-21